Revenues (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenues were as follows:


	Year Ended December 31, 2021								Year Ended December 31, 2020								Year Ended December 31, 2019
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
HIV
Atripla	$	121	$	12	$	12	$	145	$	307	$	21	$	21	$	349	$	501	$	60	$	39	$	600
Biktarvy	7,049		969		606		8,624		6,095		735		429		7,259		4,225		370		143		4,738
Complera/Eviplera	102		142		14		258		89		159		21		269		160		214		32		406
Descovy	1,397		164		139		1,700		1,526		197		138		1,861		1,078		255		167		1,500
Genvoya	2,267		391		221		2,879		2,605		490		243		3,338		2,984		664		283		3,931
Odefsey	1,076		440		52		1,568		1,172		450		50		1,672		1,180		438		37		1,655
Stribild	132		43		14		189		125		54		17		196		268		75		26		369
Truvada	314		22		35		371		1,376		27		45		1,448		2,640		101		72		2,813
Revenue share - Symtuza(1)	355		165		11		531		331		149		8		488		249		130		—		379
Other HIV(2)	15		18		17		50		25		5		28		58		30		5		12		47
Total HIV	12,828		2,366		1,121		16,315		13,651		2,287		1,000		16,938		13,315		2,312		811		16,438

Veklury	3,640		1,095		830		5,565		2,026		607		178		2,811		—		—		—		—

Hepatitis C virus (“HCV”)
Ledipasvir/ Sofosbuvir(3)	84		31		97		212		92		29		151		272		312		71		260		643
Sofosbuvir/Velpatasvir(4)	815		316		331		1,462		864		337		398		1,599		971		553		441		1,965
Other HCV(5)	119		74		14		207		132		48		13		193		182		118		28		328
Total HCV	1,018		421		442		1,881		1,088		414		562		2,064		1,465		742		729		2,936

Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy	384		34		396		814		356		29		272		657		309		21		158		488
Viread	11		28		72		111		14		34		137		185		32		69		142		243
Other HBV/HDV(6)	2		42		—		44		10		8		—		18		2		9		—		11
Total HBV/HDV	397		104		468		969		380		71		409		860		343		99		300		742

Cell Therapy
Tecartus	136		40		—		176		34		10		—		44		—		—		—		—
Yescarta	406		253		36		695		362		191		10		563		373		83		—		456
Total Cell Therapy	542		293		36		871		396		201		10		607		373		83		—		456

Trodelvy	370		10		—		380		49		—		—		49		—		—		—		—

Other
AmBisome	39		274		227		540		61		230		145		436		37		234		136		407
Letairis	206		—		—		206		314		—		—		314		618		—		—		618
Ranexa	10		—		—		10		9		—		—		9		216		—		—		216
Zydelig	26		35		1		62		31		39		2		72		47		54		2		103
Other(7)	100		80		29		209		136		45		14		195		151		43		9		203
Total Other	381		389		257		1,027		551		314		161		1,026		1,069		331		147		1,547
Total product sales	19,176		4,678		3,154		27,008		18,141		3,894		2,320		24,355		16,565		3,567		1,987		22,119
Royalty, contract and other revenues	91		196		10		297		76		241		17		334		80		244		6		330
Total revenues	$	19,267	$	4,874	$	3,164	$	27,305	$	18,217	$	4,135	$	2,337	$	24,689	$	16,645	$	3,811	$	1,993	$	22,449

_______________________________

(1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2) Includes Emtriva and Tybost.

(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5) Includes Vosevi and Sovaldi.

(6) Includes Hepcludex and Hepsera.

(7) Includes Cayston and Jyseleca.

Summarized Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:


	Year Ended December 31,
(as a percentage of total revenues)	2021		2020		2019
AmerisourceBergen Corporation	23	%	27	%	21	%
Cardinal Health, Inc.	22	%	21	%	21	%
McKesson Corporation	20	%	20	%	22	%